Stopping and Restarting Tirzepatide Gets Its Own Clinical Trial

What the stopping and restarting tirzepatide study will measure

The trial, registered as NCT07387796 and sponsored by the University of Texas at Dallas, is recruiting 40 adults between 18 and 70 who are already taking tirzepatide, the dual GIP and GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for weight management. Participants will be assessed at three points: while on treatment, after a pause of three to four weeks, and again after six to eight weeks back on it.

According to the registry record, each visit runs roughly three to four hours and includes interviews, questionnaires and cognitive tasks, a urine sample for pregnancy screening in female participants, and a brain scan using magnetic resonance imaging. The stated aims are to examine how a short pause affects hunger, mood, sleep and daily functioning, and how it alters brain chemistry and neural responses to food-related images.

That combination is unusual. Most of what is known about interrupting an incretin therapy comes from weight and metabolic measurements taken after trials end. This study is trying to capture the subjective and neurobehavioral side of the interruption — appetite, emotional well-being, quality of life — and to line those changes up against imaging collected in the same people at all three stages.

Why discontinuation became the open question in GLP-1 treatment

Interruptions in GLP-1 and dual-agonist therapy are common in practice, and they rarely happen by design. Coverage lapses, pharmacy backorders, side effects, surgery, pregnancy planning and cost all produce unplanned gaps. What has been missing is systematic data on what a gap actually does over a period measured in weeks rather than months, and on what happens on the way back in.

This matters to anyone maintaining a long protocol because a pause is not a neutral event in a log. Appetite, sleep quality and mood are precisely the variables people record between clinic visits, and they are the ones a treating clinician is most likely to ask about when deciding how to handle a restart. A study designed around those endpoints produces evidence in the same currency the patient is already tracking.

The design has a clear ceiling, though. With no comparison group and 40 participants at a single site, the study is framed as a within-subject investigation rather than a test of whether pausing is safe or advisable. Registry entries describe what investigators intend to measure and what they hypothesize; they are not results, and they carry none of the weight of a completed peer-reviewed trial.

People tracking a dual-agonist protocol through a supply gap often revisit their arithmetic on the way back in, and the tirzepatide dosage calculator handles the unit conversions involved.

The Children's Hospital Los Angeles trial listing describes a Phase 3a randomized comparison of early semaglutide re-initiation two weeks after sleeve gastrectomy against standard care in 150 youths. the Children's Hospital Los Angeles trial listing.

A second trial: restarting semaglutide after sleeve gastrectomy in youth

The tirzepatide study is not the only re-initiation question under active investigation. Children's Hospital Los Angeles is running NCT06934655, a Phase 3a randomized parallel-controlled trial in 150 young people with severe obesity who had been on a weekly semaglutide regimen for at least three months before sleeve gastrectomy. Participants are randomized either to resume weekly semaglutide starting two weeks after surgery or to standard care with no pharmacotherapy afterward.

Follow-up runs 24 months, with assessments at one month before surgery, on the day of surgery, and at one, three, six, nine, 12, 18 and 24 months post-operatively. The investigators state as their hypothesis that early re-initiation will be safe, well tolerated, and produce greater improvements in obesity, cardiometabolic risk and eating behaviors than surgery alone. That is a hypothesis in a study record, not a finding.

The clinical question is narrower than it looks. Semaglutide, a GLP-1 receptor agonist marketed as Ozempic and Wegovy, is frequently used before bariatric surgery; when and whether to bring it back afterward has been left largely to individual judgment. A randomized comparison with a two-year horizon is the first structured attempt at an answer in an adolescent population.

For the semaglutide arm of these questions, the semaglutide dosage calculator covers the same conversion work.

The head-to-head surgery and medication trial record states that no randomized comparison of gastric bypass, sleeve gastrectomy, weekly semaglutide and weekly tirzepatide has previously been conducted. the head-to-head surgery and medication trial record.

How the surgery-versus-medication comparison fits in

Sitting alongside both is NCT06803888, a Phase 4 randomized trial listed as active and no longer recruiting, with 140 participants and Ali Aminian as sponsor. It compares two common bariatric operations — Roux-en-Y gastric bypass and sleeve gastrectomy — against weekly semaglutide and weekly tirzepatide in people with severe obesity. The study record notes that no head-to-head randomized comparison of these four options has previously been done.

That record also states that these medications delivered average weight reduction of roughly 15 to 22 percent in one-year trials, a magnitude not previously achieved with medical therapy, and that existing literature suggests surgery outperforms them. Testing that assumption directly is the trial's purpose. Together, the three studies mark a shift in what the research community is asking: not whether incretin drugs work, but how they behave across interruptions, sequencing and comparison with surgery.

The endpoints these researchers chose — hunger, mood, sleep, daily functioning — map closely onto what side-effect logging is meant to capture between appointments.

What these trials will not answer

None of the three has posted results. The Dallas study is recruiting, the Los Angeles study is recruiting, and the surgery comparison is active but closed to new participants. Enrollment numbers are modest — 40, 150 and 140 — and each addresses a specific population rather than the general set of people using these drugs. A finding in adolescents after sleeve gastrectomy does not transfer to an adult on a maintenance protocol.

There is also a design point worth holding onto. A planned, supervised pause inside a research protocol, with scheduled scans and questionnaires, is not the same thing as an unplanned gap caused by a pharmacy backorder. Whatever the Dallas study reports about hunger or mood during its three-to-four-week interruption will describe that controlled scenario, and reading it as a description of any interruption would overstate what the data can support.

An interruption is easier to interpret later if it sits inside a continuous record, which is the argument for consistent adherence tracking rather than logging only on-treatment weeks.

When to expect results

Registry records for all three trials were updated in the first days of September 2026. The Los Angeles trial's 24-month follow-up window means its primary readout is years away even for participants enrolled now. The Dallas study, with three visits per participant and a compact timeline per person, could report sooner, though recruitment pace at a single site is the limiting factor. The surgery comparison, already closed to enrollment, is the nearest to a readout of the three.

Until then, the useful takeaway is that a question long handled informally between patient and prescriber is being formally studied, and that any claims circulating in the meantime about what happens when incretin therapy stops are not yet backed by these trials.

According to the University of Texas at Dallas study record, participants complete three visits of roughly three to four hours each, including questionnaires, cognitive tasks and an MRI brain scan.